M Torella1, F Del Deo1, A Grimaldi1, S A Iervolino1, M Pezzella1, C Tammaro1, P Gallo2, C Rappa3, P De Franciscis1, N Colacurci1. 1. Department of Women, Children and of General and Specialized Surgery - Second University of Studies of Naples Largo Madonna delle Grazie 1, 80138 Naples, Italy. 2. Maternal and Child Department - Cremona Hospital - A. O. Istituti Ospitalieri di Cremona Viale Concordia 1, 26100 Cremona, Italy. 3. Department of Obstetrics and Gynaecology - Buon Consiglio Fatebenefratelli Hospital Via Alessandro Manzoni 220, 80123 Naples, Italy.
Abstract
OBJECTIVE: To assess whether the orally administered combination of hyaluronic acid (HA), chondroitin sulfate (CS), curcumin and quercetin could be effective in preventing recurrent cystitis in postmenopausal women and whether its efficacy was conditioned by the concurrent use of local estrogen therapy. STUDY DESIGN: This was a prospective evaluation of 145 postmenopausal women consecutively recruited from the database of three different investigators. All women should have mild-to-moderate urogenital atrophy and a history of recurrent urinary tract infections (≥2 episodes within 6 months or ≥3 episodes within 12 months documented by positive urine cultures) during the last year. Patients were assigned to three different therapeutic regimens: the first group was treated only with vaginal estrogens, the second group only with HA, CS, curcumin and quercetin per os, and the third group was treated with HA, CS, curcumin and quercetin associated with local estrogens. We evaluated the number of patients with <2 infective episodes in the 6-month follow-up and <3 episodes in the 12-month follow-up (main aim definition) and the reduction of related symptoms through a Visual Analog Scale (VAS) and the Pelvic Pain and Urgency/Frequency (PUF) patient symptom scale. Student's t-test and chi-squared test were used for data analysis as appropriate. RESULTS: At 6-month follow up, the main aim rate was 8%, 11.1% and 25% in the three groups, respectively (p<0.05 compared to baseline only in group 3). Although the reduction in the number of recurrent episodes became significant in all groups at 1 year follow-up, the main aim rate was almost double in women receiving both local estrogens and oral therapy (group 3) compared to those receiving single treatments. The improvement of related symptoms was significant in all groups at 12-month follow-up. CONCLUSIONS: In postmenopausal women, the combination of HA, CS, curcumin and quercetin per os was effective in preventing recurrent urinary tract infections, especially if administered with vaginal estrogen therapy.
OBJECTIVE: To assess whether the orally administered combination of hyaluronic acid (HA), chondroitin sulfate (CS), curcumin and quercetin could be effective in preventing recurrent cystitis in postmenopausal women and whether its efficacy was conditioned by the concurrent use of local estrogen therapy. STUDY DESIGN: This was a prospective evaluation of 145 postmenopausal women consecutively recruited from the database of three different investigators. All women should have mild-to-moderate urogenital atrophy and a history of recurrent urinary tract infections (≥2 episodes within 6 months or ≥3 episodes within 12 months documented by positive urine cultures) during the last year. Patients were assigned to three different therapeutic regimens: the first group was treated only with vaginal estrogens, the second group only with HA, CS, curcumin and quercetin per os, and the third group was treated with HA, CS, curcumin and quercetin associated with local estrogens. We evaluated the number of patients with <2 infective episodes in the 6-month follow-up and <3 episodes in the 12-month follow-up (main aim definition) and the reduction of related symptoms through a Visual Analog Scale (VAS) and the Pelvic Pain and Urgency/Frequency (PUF) patient symptom scale. Student's t-test and chi-squared test were used for data analysis as appropriate. RESULTS: At 6-month follow up, the main aim rate was 8%, 11.1% and 25% in the three groups, respectively (p<0.05 compared to baseline only in group 3). Although the reduction in the number of recurrent episodes became significant in all groups at 1 year follow-up, the main aim rate was almost double in women receiving both local estrogens and oral therapy (group 3) compared to those receiving single treatments. The improvement of related symptoms was significant in all groups at 12-month follow-up. CONCLUSIONS: In postmenopausal women, the combination of HA, CS, curcumin and quercetin per os was effective in preventing recurrent urinary tract infections, especially if administered with vaginal estrogen therapy.
Authors: Giampaolo Mainini; Mario Passaro; Antonio Schiattarella; Pasquale De Franciscis; Mariano C Di Donna; Gennaro Trezza Journal: Prz Menopauzalny Date: 2020-10-02
Authors: Paul Loubet; Jérémy Ranfaing; Aurélien Dinh; Catherine Dunyach-Remy; Louis Bernard; Franck Bruyère; Jean-Philippe Lavigne; Albert Sotto Journal: Front Microbiol Date: 2020-07-03 Impact factor: 5.640
Authors: Pasquale De Franciscis; Gaetano Riemma; Antonio Schiattarella; Luigi Cobellis; Maria Guadagno; Salvatore Giovanni Vitale; Lavinia Mosca; Antonio Cianci; Nicola Colacurci Journal: Diagnostics (Basel) Date: 2019-10-07
Authors: Cristiane Santos Silva E Silva Figueiredo; Joice Castelo Branco Santos; José Artur de Aguiar Castro Junior; Vinícius Galvão Wakui; João F S Rodrigues; Mariana Oliveira Arruda; Andrea de Souza Monteiro; Valério Monteiro-Neto; Maria Rosa Quaresma Bomfim; Lucília Kato; Luís Cláudio Nascimento da Silva; Marcos Augusto Grigolin Grisotto Journal: Molecules Date: 2017-05-31 Impact factor: 4.411